Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Leptin promotes the osteoblastic differentiation of vascular smooth muscle cells from female mice by increasing RANKL expression.

Endocrinology | 2014

Arterial calcification is a complex and active regulated process, which results from a process of osteoblastic differentiation of vascular smooth muscle cells (VSMCs). Leptin, the product of the ob gene, mainly regulates food intake and energy expenditure and recently has been considered to be correlated with the arterial calcification. However, the mechanisms of the effects of leptin on osteoblastic differentiation of VSMCs are unknown. We used calcifying vascular smooth muscle cells (CVSMCs) as a model to investigate the relationship between leptin and the osteoblastic differentiation of CVSMCs and the signaling pathways involved. Our experiments demonstrated that leptin could increase expression of receptor activator of nuclear factor-κB ligand (RANKL) and bone morphogenetic protein 4 (BMP4), as well as alkaline phosphatase (ALP) activity, runt-related transcription factor 2 expression, calcium deposition, and the formation of mineralized nodules in CVSMCs. Suppression of RANKL with small interfering RNA abolished the leptin-induced ALP activity and BMP4 expression in CVSMCs. Leptin could activate the ERK1/2 and phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway. Furthermore, pretreatment with the ERK inhibitor PD98059 and the PI3K inhibitor LY294002 abolished leptin-induced RANKL expression and blocked the promotion of ALP activity of CVSMCs. Silencing of the leptin receptor OB-Rb with small interfering RNA abolished leptin-induced activation of ERK and Akt and the expression of RANKL and reversed the effects of leptin on ALP activity. Meanwhile, addition of Noggin (the BMP4 inhibitor) blunted the effect of leptin on ALP activity. These results show that leptin can promote osteoblastic differentiation of CVSMCs by the OB-Rb/ERK1/2/RANKL-BMP4 and OB-Rb/PI3K/Akt/RANKL-BMP4 pathways.

Pubmed ID: 24248461 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


ERK 1 (K-23) (antibody)

RRID:AB_2140110

This polyclonal targets MAPK3

View all literature mentions

RUNX2 (M-70) (antibody)

RRID:AB_2184247

This polyclonal targets RUNX2 (M-70)

View all literature mentions

RANKL (N-19) (antibody)

RRID:AB_2206074

This polyclonal targets TNFSF11

View all literature mentions

P (antibody)

RRID:AB_2224730

This polyclonal targets AKT1

View all literature mentions

Anti-β-Actin Antibody (C4) (antibody)

RRID:AB_626632

This monoclonal targets β-Actin

View all literature mentions

p-ERK (E-4) (antibody)

RRID:AB_627545

This monoclonal targets Epitope corresponding to a sequence containing phosphorylated tyr-204 of human origin

View all literature mentions

p-JNK (G-7) (antibody)

RRID:AB_628232

This monoclonal targets ND

View all literature mentions

JNK (FL) (antibody)

RRID:AB_632382

This polyclonal targets MAPK9

View all literature mentions

p38alpha/beta (H-147) (antibody)

RRID:AB_653716

This polyclonal targets MAPK14, MAPK11

View all literature mentions

Akt1/2 (N-19) (antibody)

RRID:AB_671713

This polyclonal targets Akt1/2 (N-19)

View all literature mentions